Drug intelligence / Profile preview

engeletin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Engeletin (also known as engelitin or dihydrokaempferol 3-rhamnoside) is a natural flavanonol glycoside primarily isolated from the rhizomes of *Smilax china* L. and other plant species. It is recognized for its potential therapeutic applications in metabolic disorders, particularly obesity and related inflammatory conditions. The mechanism of action for engeletin involves the stimulation of the browning process in white adipocytes, transforming them into thermogenic beige-like adipocytes. This effect is primarily mediated through the activation of the **Beta-3 adrenergic receptor (β3-AR)** and the **AMP-activated protein kinase (AMPK)** signaling pathways. Activation of these pathways leads to the up-regulation of key thermogenic and mitochondrial proteins, including **uncoupling protein 1 (UCP-1)**, **PGC-1α**, and **PRDM16**, while also promoting lipolysis and fatty acid β-oxidation. Beyond its metabolic effects, engeletin has demonstrated antioxidant and anti-inflammatory properties in various preclinical models.

Other names
EngelitinDihydrokaempferol 3-rhamnosideDihydrokaempferol3-rhamnosideDihydrokaempferol-3-rhamnosideDihydrokaempferol 3-O-alpha-L-rhamnopyranosideDihydrokaempferol3-O-alpha-L-rhamnopyranosideDihydrokaempferol-3-O-alpha-L-rhamnopyranoside
02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)ADRB3 (β3)

Beyond the preview

Go deeper on engeletin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on engeletin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call